Grant: Idea to Innovation
University of Windsor
$15,000.00
Proposal for a Market Assessment for the Development of first-in-class chemical tools to study the abnormal cyclin activation of CDK2
EF 2023-24
Résumé
A market study will be conducted to assess the viability of commercializing new tools allowing for the interference of the cell cycle to allow researchers to both understand the basic biology, and to develop new therapeutics for a variety of metabolic diseases and cancers. Recently, the applicants as inventors filed a provisional patent with the University of Windsor as 63/580,052 on September 1, 2023 to the USPTO. The cell cycle, the pathway all cells take to duplicate their DNA and split into daughter cells, is extremely tightly regulated to prevent uncontrolled cell growth or the emergence of abnormalities. There are a series of checkpoints throughout this process which are carefully gated by proteins called cyclin dependent kinases (CDKs). These CDKs are likewise tightly controlled through a series of activation steps required before they can "turn on." One of the key requirements for activation is that the CDK needs bind to a specific cyclin protein. Co-applicant Porter disclosed the existence of a family of atypical cyclins, the Spy1/Ringo family, that can override all the normal control mechanisms. When Spy1 binds to a CDK, none of the normal protein inhibitors can deactivate the protein, nor are the normal co-factors needed to turn the protein on. In effect, it locks CDK into the active form. There are no molecules that efficiently inhibit Spy1-CDK2---tool molecules that inhibit CDK2-Cyclin A/E do not work. The Trant and Porter labs, as part of their campaign to develop Spy1 inhibitors are looking to commercialize a series of tool compounds they have developed to both help identify and inhibit this complex in vitro and in vivo. These include simple active site inhibitors, fluorescent inhibitors useful for displacement assays and as identifiers of the complex, and biotinylated probes useful for protein purification. These types of chemical tools are commercially available for other related proteins, but there are none for the Spy1-CDK2 complex. As CDKs are a target of growing interest, we believe this assessment will confirm that there is a commercial market and need for these molecules and will identify key stakeholders, commercialization partners, and possible customers for this series of products.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
590745-2024
Name nom
Trant, John JF
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2024
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Proteins and peptides, amino acids
Research subject en
Biochimie
Research subject fr
Protéines et peptides, acides aminés
Application title
Proposal for a Market Assessment for the Development of first-in-class chemical tools to study the abnormal cyclin activation of CDK2
Keyword
cancer; cell cycle; cyclin dependent kinase; enzyme inhibition; fluorescence; molecular biology; small molecule chemical probe; Spy1
Application summary
A market study will be conducted to assess the viability of commercializing new tools allowing for the interference of the cell cycle to allow researchers to both understand the basic biology, and to develop new therapeutics for a variety of metabolic diseases and cancers. Recently, the applicants as inventors filed a provisional patent with the University of Windsor as 63/580,052 on September 1, 2023 to the USPTO. The cell cycle, the pathway all cells take to duplicate their DNA and split into daughter cells, is extremely tightly regulated to prevent uncontrolled cell growth or the emergence of abnormalities. There are a series of checkpoints throughout this process which are carefully gated by proteins called cyclin dependent kinases (CDKs). These CDKs are likewise tightly controlled through a series of activation steps required before they can "turn on." One of the key requirements for activation is that the CDK needs bind to a specific cyclin protein. Co-applicant Porter disclosed the existence of a family of atypical cyclins, the Spy1/Ringo family, that can override all the normal control mechanisms. When Spy1 binds to a CDK, none of the normal protein inhibitors can deactivate the protein, nor are the normal co-factors needed to turn the protein on. In effect, it locks CDK into the active form. There are no molecules that efficiently inhibit Spy1-CDK2---tool molecules that inhibit CDK2-Cyclin A/E do not work. The Trant and Porter labs, as part of their campaign to develop Spy1 inhibitors are looking to commercialize a series of tool compounds they have developed to both help identify and inhibit this complex in vitro and in vivo. These include simple active site inhibitors, fluorescent inhibitors useful for displacement assays and as identifiers of the complex, and biotinylated probes useful for protein purification. These types of chemical tools are commercially available for other related proteins, but there are none for the Spy1-CDK2 complex. As CDKs are a target of growing interest, we believe this assessment will confirm that there is a commercial market and need for these molecules and will identify key stakeholders, commercialization partners, and possible customers for this series of products.